234 related articles for article (PubMed ID: 24821594)
1. The pyrazinamide susceptibility breakpoint above which combination therapy fails.
Gumbo T; Chigutsa E; Pasipanodya J; Visser M; van Helden PD; Sirgel FA; McIlleron H
J Antimicrob Chemother; 2014 Sep; 69(9):2420-5. PubMed ID: 24821594
[TBL] [Abstract][Full Text] [Related]
2. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
[TBL] [Abstract][Full Text] [Related]
3. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Chigutsa E; Pasipanodya JG; Visser ME; van Helden PD; Smith PJ; Sirgel FA; Gumbo T; McIlleron H
Antimicrob Agents Chemother; 2015 Jan; 59(1):38-45. PubMed ID: 25313213
[TBL] [Abstract][Full Text] [Related]
4. Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Zheng X; Zheng R; Hu Y; Werngren J; Forsman LD; Mansjö M; Xu B; Hoffner S
Antimicrob Agents Chemother; 2016 Aug; 60(8):4786-92. PubMed ID: 27246779
[TBL] [Abstract][Full Text] [Related]
5. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.
Botha FJ; Sirgel FA; Parkin DP; van de Wal BW; Donald PR; Mitchison DA
S Afr Med J; 1996 Feb; 86(2):155-8. PubMed ID: 8619142
[TBL] [Abstract][Full Text] [Related]
6. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
7. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
Trials; 2020 May; 21(1):383. PubMed ID: 32370774
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
9. A quantitative adaptation of the Wayne test for pyrazinamide resistance.
Meinzen C; Proaño A; Gilman RH; Caviedes L; Coronel J; Zimic M; Sheen P
Tuberculosis (Edinb); 2016 Jul; 99():41-46. PubMed ID: 27450003
[TBL] [Abstract][Full Text] [Related]
10. Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
Forsman LD; Jonsson J; Wagrell C; Werngren J; Mansjö M; Wijkander M; Groenheit R; Hammar U; Giske CG; Schön T; Bruchfeld J
Clin Infect Dis; 2019 Sep; 69(8):1394-1402. PubMed ID: 30561569
[TBL] [Abstract][Full Text] [Related]
11. Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients.
Sheen P; Méndez M; Gilman RH; Peña L; Caviedes L; Zimic MJ; Zhang Y; Moore DA; Evans CA
J Clin Microbiol; 2009 Sep; 47(9):2937-43. PubMed ID: 19535526
[TBL] [Abstract][Full Text] [Related]
12. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.
Werngren J; Sturegård E; Juréen P; Ängeby K; Hoffner S; Schön T
Antimicrob Agents Chemother; 2012 Mar; 56(3):1253-7. PubMed ID: 22203587
[TBL] [Abstract][Full Text] [Related]
13. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
14. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
Velásquez GE; Calderon RI; Mitnick CD; Becerra MC; Huang CC; Zhang Z; Contreras CC; Yataco RM; Galea JT; Lecca LW; Murray MB
Antimicrob Agents Chemother; 2016 Nov; 60(11):6766-6773. PubMed ID: 27600032
[TBL] [Abstract][Full Text] [Related]
15. Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics.
Wilkinson D; Pillay M; Davies GR; Sturm AW
Trans R Soc Trop Med Hyg; 1996; 90(6):692-5. PubMed ID: 9015521
[TBL] [Abstract][Full Text] [Related]
16. Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment.
McAulay K; Saito K; Warrier T; Walsh KF; Mathurin LD; Royal-Mardi G; Lee MH; Ocheretina O; Pape JW; Fitzgerald DW; Nathan CF
mBio; 2018 Nov; 9(6):. PubMed ID: 30459198
[TBL] [Abstract][Full Text] [Related]
17. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.
Mphahlele M; Syre H; Valvatne H; Stavrum R; Mannsåker T; Muthivhi T; Weyer K; Fourie PB; Grewal HM
J Clin Microbiol; 2008 Oct; 46(10):3459-64. PubMed ID: 18753350
[TBL] [Abstract][Full Text] [Related]
18. Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis.
Su WJ; Feng JY; Chiu YC; Huang SF; Lee YC
Eur Respir J; 2011 Feb; 37(2):376-83. PubMed ID: 20516049
[TBL] [Abstract][Full Text] [Related]
19. Primary and acquired pyrazinamide resistance in patients with pulmonary tuberculosis treated at a referral hospital in the city of Recife, Brazil.
Ribeiro LB; Magalhães V; Magalhães M
J Bras Pneumol; 2012; 38(6):740-7. PubMed ID: 23288119
[TBL] [Abstract][Full Text] [Related]
20. [Determination of Mycobacterium tuberculosis' sensitivity to pyrazinamide on a BACTEC-960 bacteriological analyzer].
Irtuganova OA; Smirnova NS; Slogotskaia LV
Probl Tuberk Bolezn Legk; 2003; (7):40-2. PubMed ID: 12939878
[No Abstract] [Full Text] [Related]
[Next] [New Search]
